Top Markets
Coin of the day
Psyence Biomedical Ltd. Psyence Biomedical Ltd.

Psyence Biomedical Ltd.

PBM
Rangering i aksjer #40932
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines... Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
Aksjekurs
$3.20
Sist synkronisert: 2026-07-31
Markedsverdi
$60.86K
Endring (1 dag)
-4.76%
Endring (1 år)
-83.44%
Land
CA
Handel Psyence Biomedical Ltd. (PBM)

Kategori

Inntekter for Psyence Biomedical Ltd. (PBM)
Inntekter i 2026 TTM: 0
Ifølge Psyence Biomedical Ltd. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Psyence Biomedical Ltd. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE